Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic.

ABSTRACT:

Background

The COVID 19-pandemic has led physicians to change their approach to treating non-small cell lung cancer (NSCLC) to reduce hospital stays for patients.

Objectives

We aimed to assess the toxicity and efficacy of extended interval (EI) dosing of immune checkpoint inhibitors (ICIs) compared to standard dosing (SD).

Methods

In this retrospective two-center study, we included patients with stage III/IV NSCLC who were treated with ICIs with or without maintenance pemetrexed during the month before March 2020. Adverse events and efficacy were collected until June 2021. Toxicity and survival were assessed using multivariate Cox models.

Results

Among the 134 patients identified (8 stage III and 126 stage IV; 66 first line and 60 second or subsequent lines), 7

SUBMITTER: Veron M 

PROVIDER: S-EPMC9937999 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature